We are live on ! Find out more
VYGR icon

Voyager Therapeutics

138 hedge funds and large institutions have $430M invested in Voyager Therapeutics in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 47 increasing their positions, 40 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,285% more call options, than puts

Call options by funds: $830K | Put options by funds: $13K

44% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 18

18% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 40

5% more funds holding

Funds holding: 131138 (+7)

0.17% more ownership

Funds ownership: 83.06%83.23% (+0.17%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

19% less capital invested

Capital invested by funds: $528M → $430M (-$98M)

Holders
138
Holders Change
+7
Holders Change %
+5.34%
% of All Funds
2.72%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
26
Increased
47
Reduced
40
Closed
18
Calls
$830K
Puts
$13K
Net Calls
+$817K
Net Calls Change
-$839K
Name Holding Trade Value Shares
Change
Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$2.65M +$213K +14,620 +8%
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$2.63M +$2.01M +138,271 +274%
Morgan Stanley
28
Morgan Stanley
New York
$2.54M -$724K -49,819 -22%
Bank of Montreal
29
Bank of Montreal
Ontario, Canada
$2.36M +$2.41M +165,690 +5,117%
B
30
Bailard
California
$2.34M +$730K +50,200 +43%
RJFSA
31
Raymond James Financial Services Advisors
Florida
$2.19M -$579K -39,813 -20%
FT
32
Fiduciary Trust
Massachusetts
$2.17M
Squarepoint
33
Squarepoint
New York
$1.77M -$285K -19,591 -13%
Man Group
34
Man Group
United Kingdom
$1.65M +$744K +51,163 +77%
HAM
35
HHR Asset Management
New Jersey
$1.44M -$150K -10,330 -9%
Ameriprise
36
Ameriprise
Minnesota
$1.32M +$1.38M +94,888 New
Two Sigma Advisers
37
Two Sigma Advisers
New York
$1.29M +$106K +7,300 +9%
American Century Companies
38
American Century Companies
Missouri
$1.22M -$995K -68,478 -44%
AG
39
Algert Global
California
$1.22M +$720K +49,540 +130%
Invesco
40
Invesco
Georgia
$1.11M -$4.56M -313,951 -80%
Capital Fund Management (CFM)
41
Capital Fund Management (CFM)
France
$1.07M +$1.11M +76,510 New
AA
42
ALPS Advisors
Colorado
$1.05M +$22.9K +1,576 +2%
Russell Investments Group
43
Russell Investments Group
United Kingdom
$1.04M +$975K +67,064 +832%
Two Sigma Investments
44
Two Sigma Investments
New York
$1M -$58.6K -4,033 -5%
AQR Capital Management
45
AQR Capital Management
Connecticut
$983K -$108K -7,449 -10%
QI
46
QS Investors
New York
$965K -$13.1K -900 -1%
CSS
47
Cubist Systematic Strategies
Connecticut
$906K +$197K +13,562 +26%
BNP Paribas Asset Management
48
BNP Paribas Asset Management
France
$777K +$810K +55,712 New
AIMCA
49
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$770K +$802K +55,200 New
Swiss National Bank
50
Swiss National Bank
Switzerland
$739K +$17.4K +1,200 +2%

VYGR Hedge Fund Activity: Q4 2019 in Review

138 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2019, worth a combined $430M — down 19% from $528M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new VYGR positions and 18 closed out — a net gain of 8 holders — while 47 added to existing stakes and 40 trimmed.

The largest buyer was Armistice Capital, adding an estimated $7.67M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $21.2M sold.

  • 138 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2019, up from 131 in Q3 2019.
  • Funds reported $430M of Voyager Therapeutics stock for Q4 2019, down 19% quarter-over-quarter.
  • 26 funds opened new Voyager Therapeutics positions in Q4 2019 and 18 closed out, a net change of +8 holders.
  • The largest Voyager Therapeutics buyer in Q4 2019 was Armistice Capital, an estimated $7.67M added.
  • The largest Voyager Therapeutics seller in Q4 2019 was PFM Health Sciences, an estimated $21.2M sold.

Based on aggregated 13F filings for Q4 2019.